Research
JPMorgan Initiates Prelude Therapeutics With Overweight Rating, $12 PT
$PRLD
$PRLD
2 stories mentioning PRLDUpdated 6d ago
Every FINWIRES story that references PRLD, newest first.
What are analysts saying about PRLD?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on PRLD?
Wire
Prelude Therapeutics Prices $90 Million Underwritten Offering
Prelude Therapeutics (PRLD) said Monday it has priced an underwritten offering of about 18 million shares of voting common stock at $4.44 per share, along with pre-funded warrants to purchase up to about 2.3 million shares at $4.4399 each, for gross proceeds of about $90 million.The offering is expected to close on or about Tuesday, the company said.Net proceeds will be used for working capital and general corporate purposes, including the development of its product candidates, Prelude Therapeutics said.Shares of Prelude Therapeutics were 11% higher in Monday premarket trading.
$PRLD
